FDA approves new oral drug Inluriyo for advanced breast cancer

The FDA approved Inluriyo, a new oral drug for advanced breast cancer with ESR1 mutations, offering a significant breakthrough. Inluriyo targets hormone-resistant tumors by blocking estrogen receptors, reducing progression or death risk by 33-38%. It provides a convenient pill alternative. This first-in-class oral therapy addresses resistance to standard hormonal treatments, offering new hope for patients with this specific cancer type.